MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Updates From Galena Biopharma, Inc. (GALE) 0 comments
    Jul 31, 2013 2:38 PM | about stocks: GALE

    Biopharmaceutical company Galena Biopharma has moved forward with its Phase IIb trial of NeuVax (nelipepimut-S or E75) combined with Herceptin as an adjuvant treatment in HER2 1+/2+ breast cancer patients. An investigator is conducting the trial in collaboration with the company.

    Roche Holding subsidiary Genentech is responsible for providing Herceptin for the trial at no charge. Galena began enrolling patients in the trial in March 2013. The trial has been designed to randomize 300 breast cancer patients (1:1) - node positive or negative - who are disease-free following standard of care, comparing NeuVax plus Herceptin vs. Herceptin alone with a primary endpoint of disease-free survival (NYSE:DFS) at 24 months.

    Galena also recently reported data from its ongoing Phase I/IIa trial of FPB (folate binding protein or E-39) in ovarian cancer (NYSE:OC) and endometrial cancer (NYSE:EC). FBP is overexpressed in more than 90% of OC and EC, compared with limited expression in nonmalignant tissues, which is a feature that makes the drug a good immunotherapy target. Galena uses FBP (plus GM-CSF) as an adjuvant treatment for preventing cancer recurrence in high-risk OC and EC. Enrollment in the study begun in February 2012, and 20 patients have been enrolled to date. FBP-treated patients had an 11.1% recurrence, while untreated patients had a 27.3% occurrence - representing a 59% reduction.

    Galena's Abstral (fentanyl) sublingual tablets, which are indicated for managing breakthrough pain in cancer patients 18 years and older who are already receiving and are tolerant to opioid therapy, is projected to contribute $1.5 million in revenue in 2013 and $8.2 million in 2014. This is contrasted with management's guided revenues of $1.5 million to $3 million in 2013 and $8 million to $12 million in 2014. The company's 10-year DCF values NeuVax at $4/share and Abstral at $1/share. At this stage, Galena is not assigning a market value to FBP. The company believes its long-term risk-reward profile is favorable.

    A biopharmaceutical company based in Portland, Ore., Galena Biopharma is engaged in the development of innovative, targeted oncology treatments to address major unmet medical needs in the advancement of cancer care. For more information about Galena Biopharma, visit galenabiopharma.com.

    Please see disclaimer on the MissionIR website


    Stocks: GALE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.